---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-046719"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2022-02-18T23:59:59+00:00"
generated_at: "2026-06-27T06:31:52.102262+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics appoints Harlan Waksal as Executive Chair; adopts inducement award plan

## Summary
- Harlan Waksal appointed as Class II director, Chairperson, and Executive Chair; base salary $200,000.
- Waksal receives option to purchase 520,000 shares at $4.21, vesting based on market cap targets over 5 years.
- CEO Maria Palasis granted option for 175,000 shares; both executives eligible for 1% of market cap bonus on change in control ≥ $750M.
- Lyra adopts 2022 Inducement Award Plan reserving 520,000 shares for new hires under Nasdaq Rule 5635(c)(4).

## SEC filing metadata
- accession: 0001193125-22-046719
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2022-02-18T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/0001193125-22-046719-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/d309078d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-046719
- JSON: https://secwatch.observer/filing/0001193125-22-046719.json
- Plain text: https://secwatch.observer/filing/0001193125-22-046719.txt

## Key facts
- Executive change
  Harlan Waksal was appointed as Executive Chair at Lyra Therapeutics, Inc..
  - Action: appointed
  - Role: Executive Chair
  source text: On February 16, 2022, the Board of Directors of Lyra Therapeutics, Inc. (the “Company”) appointed Harlan Waksal, M.D. as a Class II director of the Company and Chairperson of the Board, and as the Executive Chair and an executive officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000119312522046719/0001193125-22-046719-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.